Latest News
News Functions
Additional Functions
21 May 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013
14 May 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index
Synergy Pharmaceuticals
Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index
9 May 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results
16 April 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Announces Closing of Public Offering of Shares of Common Stock
11 April 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of Common Stock
9 April 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc. Announces Public Offering of Common Stock
18 March 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Reports 2012 Fourth Quarter and Full-Year Financial Results
15 March 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals to Present Study Results From Plecanatide Phase IIb/III Trial in Late-Breaking Clinical Abstract at Digestive Disease Week 2013
11 February 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market
28 January 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis
17 January 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals
15 January 2013
Synergy Pharmaceuticals
Synergy Pharmaceuticals Announces Approval of Merger With Callisto Pharmaceuticals and Other Actions at Annual Meeting of Stockholders
2 January 2013
Synergy Pharmaceuticals
Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation
28 December 2012
Synergy Pharmaceuticals
Synergy Pharmaceuticals Completes Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Gastrointestinal Diseases
27 December 2012
Synergy Pharmaceuticals
Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C)
14 December 2012
Synergy Pharmaceuticals
Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis
22 October 2012
Synergy Pharmaceuticals
Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate Cyclase-C, Highlighting a Novel Approach to Treating Ulcerative Colitis in Humans
Synergy Pharmaceuticals
Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation
Synergy Pharmaceuticals
Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate Cyclase-C, Highlighting a Novel Approach to Treating Ulcerative Colitis in Humans
Synergy Pharmaceuticals
Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation
Synergy Pharmaceuticals
Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis
Synergy Pharmaceuticals
Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis
12 September 2012
Synergy Pharmaceuticals
Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases
Synergy Pharmaceuticals
Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases
9 April 2012
Synergy Pharmaceuticals
Synergy Pharmaceuticals Achieves Halfway Mark in Enrollment on Plecanatide Phase II/III Trial in Chronic Idiopathic Constipation
Synergy Pharmaceuticals
Synergy Pharmaceuticals Achieves Halfway Mark in Enrollment on Plecanatide Phase II/III Trial in Chronic Idiopathic Constipation